文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Ahluwalia A, Peers S H, Flower R J

Department of Biochemical Pharmacology, William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London.

Br J Pharmacol. 1992 Jul;106(3):628-31. doi: 10.1111/j.1476-5381.1992.tb14386.x.

A model has been developed to compare the inhibitory effects of the topical steroid, betamethasone-17-valerate, to those of systemically administered betamethasone upon oedema responses induced by 5-hydroxytryptamine (5-HT), platelet activating factor (PAF) and zymosan-activated serum (ZAS) +/- prostaglandin E1 (PGE1), measured in the rat skin by use of 125I-labelled human serum albumin. 2. Systemic betamethasone had a selective, time- and dose-dependent inhibitory effect upon oedema treatment, with 1 mg kg-1 and a 3 h pretreatment having the greatest effect of the doses and times employed. 3. Topical betamethasone inhibited the oedema responses to all of the stimuli showing no apparent selectivity. 4. Topical betamethasone inhibits inflammatory stimuli in a different manner from systemic betamethasone. The broad spectrum of inhibition suggests that topical betamethasone acts by affecting a fundamental feature of the inflammatory response common to all of the stimuli.

已建立一种模型，用于比较局部用类固醇倍他米松-17-戊酸酯与全身给药的倍他米松对5-羟色胺（5-HT）、血小板活化因子（PAF）和酵母聚糖激活血清（ZAS）+/-前列腺素E1（PGE1）诱导的水肿反应的抑制作用，该水肿反应通过使用125I标记的人血清白蛋白在大鼠皮肤中进行测量。2. 全身用倍他米松对水肿治疗具有选择性、时间和剂量依赖性抑制作用，在所采用的剂量和时间中，1 mg/kg-1及3小时预处理的效果最佳。3. 局部用倍他米松抑制对所有刺激的水肿反应，未表现出明显的选择性。4. 局部用倍他米松与全身用倍他米松抑制炎症刺激的方式不同。广泛的抑制作用表明，局部用倍他米松通过影响所有刺激共有的炎症反应的基本特征来发挥作用。

Ahluwalia A, Peers S H, Flower R J

Department of Biochemical Pharmacology, William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London.

Br J Pharmacol. 1992 Jul;106(3):628-31. doi: 10.1111/j.1476-5381.1992.tb14386.x.

A model has been developed to compare the inhibitory effects of the topical steroid, betamethasone-17-valerate, to those of systemically administered betamethasone upon oedema responses induced by 5-hydroxytryptamine (5-HT), platelet activating factor (PAF) and zymosan-activated serum (ZAS) +/- prostaglandin E1 (PGE1), measured in the rat skin by use of 125I-labelled human serum albumin. 2. Systemic betamethasone had a selective, time- and dose-dependent inhibitory effect upon oedema treatment, with 1 mg kg-1 and a 3 h pretreatment having the greatest effect of the doses and times employed. 3. Topical betamethasone inhibited the oedema responses to all of the stimuli showing no apparent selectivity. 4. Topical betamethasone inhibits inflammatory stimuli in a different manner from systemic betamethasone. The broad spectrum of inhibition suggests that topical betamethasone acts by affecting a fundamental feature of the inflammatory response common to all of the stimuli.

已建立一种模型，用于比较局部用类固醇倍他米松-17-戊酸酯与全身给药的倍他米松对5-羟色胺（5-HT）、血小板活化因子（PAF）和酵母聚糖激活血清（ZAS）+/-前列腺素E1（PGE1）诱导的水肿反应的抑制作用，该水肿反应通过使用125I标记的人血清白蛋白在大鼠皮肤中进行测量。2. 全身用倍他米松对水肿治疗具有选择性、时间和剂量依赖性抑制作用，在所采用的剂量和时间中，1 mg/kg-1及3小时预处理的效果最佳。3. 局部用倍他米松抑制对所有刺激的水肿反应，未表现出明显的选择性。4. 局部用倍他米松与全身用倍他米松抑制炎症刺激的方式不同。广泛的抑制作用表明，局部用倍他米松通过影响所有刺激共有的炎症反应的基本特征来发挥作用。